Northwest Biotherapeutics (NWBO) Interest Expenses (2010 - 2026)

Northwest Biotherapeutics' Interest Expenses history runs 17 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 46.44% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $9.2 million, a 29.91% decrease from a year earlier, with the FY2025 full-year figure at $8.7 million, down 96.91% from the prior year.
• Interest Expenses retreated to $2.3 million in Q1 2026 per NWBO's latest filing, from $2.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $114.6 million in Q3 2022 and bottomed at -$3.2 million in Q4 2023.
• The 5-year median for Interest Expenses is $1.7 million (2023), against an average of $9.0 million.
• Across the five-year window, Interest Expenses jumped 7045.7% in 2022 and plunged 348.74% in 2023, its largest moves.
• Year by year, Interest Expenses stood at $1.3 million in 2022, then plunged by 348.74% to -$3.2 million in 2023, then jumped by 345.15% to $7.7 million in 2024, then tumbled by 66.09% to $2.6 million in 2025, then dropped by 10.53% to $2.3 million in 2026.
• Per Business Quant, the three latest NWBO Interest Expenses figures stand at $2.3 million (Q1 2026), $2.6 million (Q4 2025), and $2.6 million (Q3 2025).